Pax6 protein was detected on CRALBP promoter region in Chromatin IP experiments and was able to activate CRALBP promoter in vitro. All our data suggest that CRALBP is a direct immediate target of Pax6. Our data provide insights into molecular cascade acting down-stream of Pax6 during development.
Methods and materials

Chromatin Immunoprecipitation (ChIP) Assay
Mouse embryonic cortex (E14.5 or E 15.5) was used as a tissue source of chromatin.
Cortex tissues were homogenized in 1x phosphate-buffered saline (10ml for 10-14 hemispheres of cortex tissue) containing protease inhibitors (Roche Applied Science).
Protein-DNA complexes were cross-linked in 1% formaldehyde for 10 min at 37 o C in a water bath incubator. Cross-linking of protein-DNA complexes was terminated with three washes in 1x phosphate-buffered saline. Samples were then processed using a ChIP assay kit, essentially as described by the manufacturer (Upstate biotechnology, Lake Placid, NY). In brief, cells were lysed in SDS lysis buffer with protease inhibitors, then sonicated using a water bath sonicator, super RK 103H from Schütt labortechnik (Goettingen, Germany) to shear DNA to fragments with a length of 100-1000 bp. To reduce nonspecific background, the cell lysates were precleared by incubation with salmon sperm DNA/protein A-agarose slurry. The agarose beads were pretreated with 2%
BSA before the preclearing step as suggested by the manufacturer. Supernatants from the preclearing step were incubated with (1: 500) rabbit anti-Pax6 polyclonal IgG (Covance), at 4 °C overnight. Cortex from Pax6 mutant mice were used as a negative control.
Chromatin-antibody complexes were precipitated by incubation with Protein A-agarose beads. Chromatin was eluted from the beads after washes in several buffers provided with the kit. The DNA-protein cross-links in all samples were reversed by incubation for 4 h at 65 °C with 0.2M NaCl followed by proteinase K treatment for 1 h at 45 °C. DNA was isolated by phenol/chloroform extraction and ethanol precipitation. PCR was performed with primers that flank known and putative Pax6 binding sites.
As a positive control, the following primers were used against Pax6 promoter region All PCR products were separated by 1.5% agarose gel electrophoresis in TAE buffer.
DNA was loaded using OrangeG buffer, and 100 bp DNA markers (Invitrogen) was used at a concentration of 50ng/μl.
In situ Hybridization
Wild-type and Pax6 mutant brain and spinal cord of E14.5 mice were isolated, fixed in 4% PFA, dehydrated in increasing concentrations of ethanols and fixed in paraffin blocks. 10μm thick sections were cut and In situ hybridization with RNA probes was performed as stated earlier .
Immunohistochemistry
Immunohistochemistry was performed on 10μm thick cryosections of E14.5 wild-type brain and eye. Freshly isolated brains were fixed in 4% PFA for 2-4 hrs at 4°C, soaked in 30% sucrose overnight and cryopreserved in tissue-tek (Sakura Finetek Zoeterwoude, NL). Immunohistochemistry was carried out with rabbit anti-CRALBP (kindly provided by Prof. John Saari, University of Washington, Seattle; 1:500) and mouse monoclonal Pax6 (Developmental Studies Hybridoma Bank, Iowa; 1:100) antibodies. Sections were blocked in 1% BSA and 0.5% Tween in PBS for 1hr, rinsed in PBS and incubated for 2 hrs with primary antibodies at RT. Primary antibodies were washed in PBS and detected using fluorescent secondary antibody (1:1000) for 1 hr. Sections were rinsed in PBS and visualized using a fluorescent microscope after mounting with Prolong Gold antifade reagent with DAPI (Invitrogen).
Plasmid constructs and luciferase reporter assay
Dual-luciferase Reporter Assay System was used to measure luciferase activity Readings obtained for firefly luciferase were divided with readings obtained for renilla luciferase to normalize the levels of the experimental reporter activity.
Histology
Freshly isolated brains were dehydrated with a series of ethanol wash steps (30%, 50%, 70%, 80%, 90%, 95% and 100%) for atleast 2 hrs each, transferred to toluol for 6 hrs, soaked in fresh paraplast, twice, overnight and then embedded in paraffin blocks for sectioning.
Image acquisition
Bright and dark field images were obtained with a light microscope (Olympus). To obtain fluorescent images, a Zeiss confocal microscope was used (Zeiss LSM 510 META).
Images obtained were edited using Adobe Photoshop.
Results
CRALBP expression is down-regulated by Pax6 deletion
In order to identify Pax6 downstream targets in the developing neocortex we carried out microarray analysis of Pax6 -/-mutant and wild type mice (Supplementary data table 1; http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32271). Pax6 is highly expressed in the mouse cerebral cortex at embryonic day E14.5, therefore we selected (Fig: 1c) . In Pax6 mutant cortex the expression of CRALBP was abolished in all these regions (Fig: 1d) .
Since Pax6 is also expressed in the spinal cord, we investigated the expression of CRALBP in the spinal cord using in situ hybridization. In wt spinal cord, Pax6 and CRALBP are expressed in the VZ (Fig: 1f and g ) of the spinal cord. No expression of CRALBP was detected in the spinal cord in Pax6 mutants (Fig: 1h) .
Next, we addressed whether Pax6 and CRALBP are expressed in the same cells. To study protein expression, a double immunohistochemistry (IHC) was performed on E14.5 wt and Pax6 mutant brains. In the wt brain, CRALBP was expressed in all Pax6 expressing regions. These regions included pallial-subpallial boundary (PSPB) of the cortex and regions around the third ventricle in the thalamus (Fig: 2) . In all these regions CRALBP showed sharp boundaries of expression that coincided with Pax6. Expression of Pax6 and CRALBP was excluded from the cortical hem (Fig: 2a-c) . We did not find any CRALBP expressing cells that did not express Pax6. In the neocortex, expression of CRALBP protein was not only detected in the ventricular zone but also in the cortical plate (Fig:   2e ), while Pax6 expression was confined to the VZ. This can be explained by the fact that VZ is populated by radial glia cells that reside in the VZ but extent their processes towards pial surface. Therefore, Pax6 as a nuclear protein is detected in the VZ (region where all cell nuclei are located), on the other hand, CRALBP is a cytoplasmic protein and is more likely to be detected in the radial processes. The complete abolishment of CRALBP mRNA expression in the cortex and spinal cord of Pax6 mutant mice suggested that CRALBP could be a direct downstream target of Pax6 (Fig: 1d and h) .
Interestingly, CRALBP and Pax6 protein do not seem to co-express in the developing eye. At E 14.5, Pax6 is expressed in the neuroretina (NR) whereas CRALBP is expressed in the retinal pigment epithelium (RPE) that surrounds the neuroretina (Fig: 2m and n) .
Our results indicate that Pax6 and CRALBP are not co-localized in the eye (Fig: 2o) . It was not possible to study expression of CRALBP in the eye of Pax6 mutants because they fail to develop an eye.
Chromatin immunoprecipitation assay (ChIP) reveals Pax6 binding sites on CRALBP promoter
Our expression data ( Fig: 1 and 2) suggested that Pax6 directly regulates the expression of CRALBP. Since putative Pax6 binding sites are known , we inspected the 5' upstream region of exon1 of the mouse CRALBP gene. We were able to identify 6 putative Pax6 binding sites within 6 kb upstream of the first exon. The consensus sequence "CACGTG" was located at 5.7 kb, 4.6 kb and 2 kb upstream (Fig: 3a) , and the consensus sequence "GGTGGAA" was located at 3.4 kb, 2.9 kb and 2 kb (Fig: 3a) upstream of CRALBP exon1. In order to perform Chromatin immunoprecipitation assay (ChIP), we chose a time point during development where Pax6 is known to be highly active. By E14.5, expression of Pax6 can be detected throughout the anterior-posterior axis of the dorsal telencephalon in the ventricular zone and the subventricular zone . DNA-protein complexes isolated from E14.5 cortex were precipitated with Pax6 antibody and amplified using primers against sequences flanking Pax6 binding sites in CRALBP upstream genomic region. Pax6 antibody precipitated two DNA fragments from CRALBP 5´ region, at 2kb and 2.9kb upstream of exon1 (Fig. 3c) . Similar experiment was also performed by precipitating DNA-protein complexes using Pax6 antibody from Pax6 mutant cortex tissue. As predicted, we did not amplify any DNA above background in the PCR reaction (data not shown). Our in vivo results indicate that Pax6 binds the putative promoter region of CRALBP.
Pax6 activates CRALBP promoter in vitro
To evaluate whether binding of Pax6 on CRALBP promoter induces expression of CRALBP, a luciferase-reporter assay was performed. CHO cells were transiently cotransfected with Pax6 cDNA plasmid and with a plasmid that contains previously identified CRALBP promoter coupled with luciferase gene . The CRALBP promoter plasmid also contains the 5' upstream sequence of exon 1 of CRALBP gene that were positive in our ChIP experiments (see above). Co-transfected cells were harvested 24hrs after transfection and luciferase activity was measured. The reporter activity of CRALBP promoter plasmid was significantly increased with increasing concentrations of Pax6 cDNA plasmid, whereas the control G5-luciferase reporter activity showed only a basal level of expression (Fig: 4) . These in vitro experiments indicate that Pax6 can positively regulate the activity of CRALBP promoter in vitro. In order to find out whether any aspects of Pax6 mutant phenotype where recapitulated in CRALBP knock-out animals we analyzed CRALBP mutant brains. We failed to detect any changes in the developing brain of CRALBP mice. Both the overall morphology and cortical layering were not changed. We did not detect any changes in the neuronal migration, proliferation or radial glia morphology during embryonic development (data not shown).
Discussion
Here, we identified CRALBP as a direct down-stream target of Pax6 transcription factor.
Pax6 is expressed in the neocortical ventricular zone (VZ), pallial-subpallial (PSPB) boundary and the thalamus (Fig: 1b) . CRALBP was found to be expressed in all these regions (Fig: 1c) . The borders of CRALBP protein expression coincided with Pax6 expression borders in various regions of the neocortex and thalamus (Fig: 2a-l) .
Interestingly, CRALBP protein expression was also detected throughout the cortical plate (Fig: 2e) , while Pax6 protein expression was limited to the VZ (Fig: 2d) . There are two possible ways to explain why CRALBP protein is detected all over the cortex while the mRNA is seen only in the VZ. One possibility is that young neurons derived from cortical progenitors in the VZ continue expressing CRALBP after its expression was initiated by Pax6 in the progenitors. Even though these neurons migrate away from the VZ towards the cortical plate, we continue to observe CRALBP protein possibly due to high stability and low turnover rate of the protein. Second possibility is that CRALBP protein, being produced by Pax6 positive radial glia progenitors, is transported along radial glial processes towards the pial surface. This however does not explain why CRALBP staining cannot delineate individual radial glial processes. Pax6 is also expressed in the differentiating field of the amygdala and in the hypothalamus surrounding the third ventricle ( Fig: 1b; indicated by double arrow heads) . However, we did not find expression of CRALBP in these regions (Fig: 1c) . Since the expression of a gene might depend on binding of many transcription co-factors, such co-factors required for CRALBP expression could be lacking in these regions.
Abolishment of CRALBP expression in the spinal cord of Pax6 mutants (Fig: 1h) indicates that CRALBP is a target of Pax6 not only in the neocortex but also in other regions of the central nervous system. This also implies that CRALBP might play a role in Pax6 mediated development of the spinal cord.
Using chromatin immunoprecipitation assay, we showed that Pax6 binds to two sites upstream of exon1 of CRALBP gene, at 2kb and 2.9kb (Fig: 3c) . Additionally, we could confirm the regulatory activity of Pax6 on CRALBP promoter in vitro in luciferase reporter assay (Fig: 4) .
Pax6 is considered a master regulatory gene of eye development . We found expression of Pax6 in the neuroretina (NR), (Fig: 2m) and that of CRALBP in the retinal pigment epithelium (RPE) that surrounds the neuroretina (Fig: 2n) . During eye morphogenesis, Pax6 is expressed in the optic vesicle (OV) and the surface ectoderm (SE) that surrounds the OV. SE thickens to form the lens placoid (LP), whereas the distal OV invaginates to form the optic cup (OC) with the inner layer developing into the NR . The optic vesicle contains bipotential progenitors which can give rise to both RPE and NR cell types.
Separation of progenitors into NR and RPE domains is mediated by external cues . We suggest that expression of Pax6 in the bipotential progenitor cells of the OV promotes CRALBP expression. After receiving signals from external cues, the bipotential progenitors differentiate into NR and RPE cells. The RPE (expressing CRALBP) then migrate and occupy the periphery surrounding the NR (Fig: 2n) . After the optic cup is formed, Pax6 is downregulated in the optic stalk and the RPE, but retained in the neuroretina . This could possibly explain the expression of CRALBP and Pax6 in distinct non-overlapping regions of the eye (Fig: 2o) .
We did not observe any defects in either layer-specification or migration of neurons in CRALBP mutants. However, it is probable that other retinal binding proteins (RBP's) expressed in the brain compensate for the loss of CRALBP. Further experiments need to be carried out to uncover the role of CRALBP in embryonic development. 
